Medtech company Symbiome.io, which analyzes the intestinal flora in the faeces, receives a multi-million investment from Add Health Media. Collaborations with researchers can also lead to new insights into what a healthy intestinal flora is and how the composition of bacteria can be affected through lifestyle changes.
Symbiome is the first Swedish company to perform analyzes of the intestinal flora. Analyzing the intestinal flora, also called the intestinal microbiome, is considered to be the next major area of research after DNA. Most studies show that the intestinal flora can be associated with direct stomach problems such as IBS, bloating and constipation. It has also been possible to associate the intestinal flora with ailments that one may not immediately think about, such as obesity, mental health, skin problems and stress.
– We see that knowledge in this area is growing very fast and that data from the analyzes provide important knowledge. With Symbiome, we see a new way of gaining knowledge together with the customers who order the analyzes. Discussions are now being held with researchers to find insights into the amount of samples that come into the company, says Tobias Perdahl, specialist in internal medicine and board member of Add Health Media.
Symbiome’s US counterpart, uBiome, has received a great deal of attention, as well as investments of half a billion. The value in the company is considered to lie in precisely the data collected via the many analyzes. The fact that the market for analysis of the intestinal flora is expected to increase significantly is due to the fact that, unlike DNA, there is an opportunity to influence and improve one’s own intestinal flora through lifestyle changes.
– With the investment, we will be able to reach more people faster and develop our service significantly. We know that there is an incredibly great need to know if the intestinal flora is out of balance. We conducted a test sale for a few days and the response was overwhelming, says Villjam Edström, CEO and founder of Symbione.
Add Health Media and 3TInvest are now investing a total of SEK 3 million in a new share issue in the company. You are joined by the former hockey player and now the business angel Mattias Weinhandl, who also chooses to invest in Symbiome.
For more information:
Villjam Edström, CEO, Symbiome
[email protected] , 0702226668
Johan Bloom, Business Development, Add Health Media AB
[email protected] , 0733-64 84 90
About Symbiome
Symbiome works with analysis of the intestinal and other bacterial flora. The cost of an analysis is SEK 1,890, which the customer pays for themselves via www.symbiome.io The goal is to gain insights and recommendations for living a better life.
About Add Health Media
Add Health Media is one of the Nordic region’s largest media houses in health and medicine and runs DOKTORN for the general public and patients, which includes a newspaper, brochure stand and waiting room TV, as well as one of the Nordic region’s most visited websites www.doktorn.com. Add Health Media also runs Praktisk Medicin, www.praktisktmedicin.se, a decision support for healthcare staff, and invests in new start-ups in e-health, such as Doctrin, Mindler, Nurse & Doc, Medicheck, Remisshjälpen, FindOut Diagnostic, ScientificMed, Picture My Life and Healthmakers.
Add Health Media (AHM) is investing in strengthening its presence in all Nordic countries and is now appointing Rikard Ekberg as CEO. AHM is already…
2022/01/17